(Q34541472)

2 July 2019

review article

1 reference

title

Pregabalin for pain in fibromyalgia in adults (English)

1 reference

2 July 2019

0 references

3

1 reference

2 July 2019

author name string

Malene Cording

series ordinal

2

1 reference

2 July 2019

Simon Law

series ordinal

4

1 reference

2 July 2019

Tudor Phillips

series ordinal

5

1 reference

2 July 2019

publication date

29 September 2016

1 reference

2 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

2 July 2019

volume

9

1 reference

2 July 2019

page(s)

CD011790

1 reference

2 July 2019

A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The fibromyalgia family study: a genome-wide linkage scan study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

An internet survey of 2,596 people with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The visual analogue pain intensity scale: what is moderate pain in millimetres?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Milnacipran for pain in fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Influence of trial sample size on treatment effect estimates: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Association between analytic strategy and estimates of treatment outcomes in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia syndrome. General principles and coordination of clinical care and patient education

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia syndrome: a somatoform disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Drugs for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia and neuropathic pain--differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Candidate gene studies of fibromyalgia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

EULAR revised recommendations for the management of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Gabapentin for chronic neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Duloxetine use in chronic painful conditions--individual patient data responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Worldwide epidemiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Etiology and pathophysiology of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Pregabalin in fibromyalgia--responder analysis from individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

What is fibromyalgia, how is it diagnosed, and what does it really mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Small fibre pathology in patients with fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Anticonvulsants for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011790.PUB2

Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study

21 January 2018

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.

1 reference

12 December 2020

Management of fibromyalgia syndrome--an interdisciplinary evidence-based guideline

1 reference

12 December 2020

Patient-centered perspective on treatment outcomes in chronic pain

1 reference

12 December 2020

[Influence of depression on fibromyalgia : A systematic review]

1 reference

12 December 2020

Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia

1 reference

12 December 2020

An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia

1 reference

12 December 2020

Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin

1 reference

12 December 2020

1 reference

12 December 2020

10.1002/14651858.CD011790.PUB2

Identifiers

DOI

1 reference

2 July 2019

release_efhobm3vavc25inwao74fhcrda

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/efhobm3vavc25inwao74fhcrda

24 November 2022

mapped directly with Wikidata item

PMCID

6457745

1 reference

2 July 2019

PubMed ID

27684492

1 reference

2 July 2019